Diagnostic performance of the urinary bladder carcinoma antigen elisa test and multiparametric dna/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma

Cancer

Volumn 92, Issue 11, 2001, Pages 2811-2819

  Sánchez Carbayo, Marta ^a,b   Ciudad, Juana ^a   Urrutia, Manuel ^a   Alejandro Navajo, Juan ^a   Orfao, Alberto ^a  

^a Centro de Investigacion del Cancer   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder neoplasia; Cytokeratin; DNA ploidy; Urinary bladder carcinoma (UBC) antigen; Urine

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; UNCLASSIFIED DRUG; URINARY BLADDER CARCINOMA ANTIGEN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DNA CONTENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINALYSIS;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; FLOW CYTOMETRY; HUMANS; KERATINS; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 0035575782     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011201)92:11<2811::AID-CNCR10101>3.0.CO;2-T     Document Type: Article

References (40)

1. Biology and management of bladder cancer
2. New methods for detection of bladder cancer
3. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer
4. Current concept in biomarker technology for bladder cancers
5. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder
6. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker network for bladder cancer
7. Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract
8. A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients
9. Initial evaluation of UBC as a tumor marker for bladder cancer
10. Comparative sensitivity of urinary CYFRA 21-1, UBC, TPA and NMP22 in the detection of bladder cancer
11. Keratins as biochemical markers of epithelial differentiation
12. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured ceils
13. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: The ISOBM TD5-1 Workshop
14. Deoxyribonucleic acid measurements in transitional carcinomas: Comparison of flow and image cytometry techniques
15. Consensus review of the clinical utility of DNA cytometry in bladder cancer
16. Dual-parameter immunoflow cytometry in diagnosis and follow-up of patients with bladder cancer
17. Flow cytometry study cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors
18. Guidelines for implementation of clinical DNA cytometry
19. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group
20. Is voided urine suitable for flow cytometric DNA analysis?
21. Application of antibodies to intermediate filament proteins as tissue-specific probes in the flow cytometric analysis of complex tumors
22. Tissue-specific markers in flow cytometry of urological cancers: Cytokeratins in bladder carcinoma
23. Initial evaluation of a new epithelial antigen (T16) for bivariate flow cytometry of bladder tumors
24. Failure of anticytokeratin 18 antibody to improve flow cytometric detection of bladder cancer
25. The predictive value of flow cytometry and urinary cytology in the follow-up of patients with transitional cell carcinoma of the bladder
26. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors
27. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder
28. Comparative analysis of DNA flow cytometry and cytology of bladder washings: Review of discordant cases
29. Flow and image cytometry for DNA analysis in bladder washings: Improved concordance by using internal reference for flow
30. The diagnostic value of flow cytometric DNA analysis in bladder cancer: Comparison with conventional cytology
31. DNA ploidy pattern of flow cytometry as indicator of malignancy and prognosis in bladder cancer
32. Staging of cancer at genitourinary sites
33. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis
34. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma
35. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer
36. Analysis of the performance of pathologists in the grading of bladder tumors
37. The relative value of cytometry and cytology in the management of bladder cancer: The Memorial Sloan-Kettering Cancer Center experience
38. Role of urinary cytology and urinary deoxyribonuleic acid flow cytometry in the diagnosis of bladder cancer
39. Serial tissue polypeptide specific antigen determinations in the follow-up of hormone treated carcinoma of the prostate